This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Summary statistics from individual studies.
Number of primary studies included
At least two studies were included in the review.
Methods of combining primary studies
Narrative method.
Investigation of differences between primary studies
Results of the review
63% of health care workers who initiate zidovudine (AZT) chemoprophylaxis complete therapy. Health care workers who fail to complete therapy have a risk of seroconversion similar to that of those who are untreated. The complication rate is 44% in treated patients and 31% in those who do not complete treatment. The seropositivity rate of the source of exposures is 35%. The seroconversion rate in an untreated health care worker exposed to an HIV-positive source is 0.3%. Single drug therapy with AZT is 80% effective in preventing seroconversion. The three-drug regimen was assumed to be 100% effective in preventing seroconversion. The prevalence of HIV positivity in University Hospital patients whose HIV status is unknown was approximately 35%. The overall incidence of side effects of treatment was 39%. These data formed the principal input parameters to the decision tree.
Measure of benefits used in the economic analysis
Quality-adjusted life years (QALYs) and the number of cases that would be prevented if 100,000 exposures were treated (rather than not treated) were used as the measures of benefit. The impact of developing HIV disease on quality of life was taken from a study published in 1997. It was assumed that HIV infection occurred at 26 years of age and that patients would survive for 12 years from time of infection until death. QALYs were discounted at an annual rate of 3%.
Direct costs
Direct costs were discounted at an annual rate of 3%. Quantities and costs were reported separately. Direct costs included wholesale costs of drugs, staff time devoted to risk assessment and counselling, and the cost of follow-up laboratory testing. The quantity/cost boundary adopted was that of the health service. The estimation of cost and quantities was based on actual data. Estimated costs were based on the experience at New York Presbyterian Hospital and a study published in 1997. The price year was 1996.
